Diagnosing mycosis fungoides after initiation of therapy with dupilumab: a case report and literature review

International Journal of DermatologyEarly View Correspondence Diagnosing mycosis fungoides after initiation of therapy with dupilumab: a case report and literature review Di Yan MD, MS, Di Yan MD, MS Department of Dermatology, New York University, New York, NY, USASearch for more papers by this authorVignesh Ramachandran MD, Corresponding Author Vignesh Ramachandran MD [email protected] orcid.org/0000-0002-4958-2182 Department of Dermatology, New York University, New York, NY, USASearch for more papers by this authorGillian Weston MD, Gillian Weston MD Department of Dermatology, New York University, New York, NY, USASearch for more papers by this authorRandie H. Kim MD, PhD, Randie H. Kim MD, PhD Department of Dermatology, New York University, New York, NY, USA Section of Dermatopathology, Department of Dermatology, New York University, New York, NY, USASearch for more papers by this authorJo-Ann Latkowski MD, Jo-Ann Latkowski MD Department of Dermatology, New York University, New York, NY, USASearch for more papers by this author Di Yan MD, MS, Di Yan MD, MS Department of Dermatology, New York University, New York, NY, USASearch for more papers by this authorVignesh Ramachandran MD, Corresponding Author Vignesh Ramachandran MD [email protected] orcid.org/0000-0002-4958-2182 Department of Dermatology, New York University, New York, NY, USASearch for more papers by this authorGillian Weston MD, Gillian Weston MD Department of Dermatology, New York University, New York, NY, USASearch for more papers by this authorRandie H. Kim MD, PhD, Randie H. Kim MD, PhD Department of Dermatology, New York University, New York, NY, USA Section of Dermatopathology, Department of Dermatology, New York University, New York, NY, USASearch for more papers by this authorJo-Ann Latkowski MD, Jo-Ann Latkowski MD Department of Dermatology, New York University, New York, NY, USASearch for more papers by this author First published: 22 March 2023 https://doi.org/10.1111/ijd.16641 Conflict of interest: None. Funding source: None. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL No abstract is available for this article. References 1Gooderham MJ, Hong HC, Eshtiaghi P, Papp KA. Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018; 78(3 Suppl 1): S28– 36. 2Geskin LJ, Viragova S, Stolz DB, Fuschiotti P. Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation. Blood. 2015; 125(18): 2798– 805. 3Steck O, Bertschi NL, Luther F, Berg J, Winkel DJ, Holbro A, et al. Rapid and sustained control of itch and reduction in Th2 bias by dupilumab in a patient with Sézary syndrome. J Eur Acad Dermatol Venereol. 2021; 35(6): 1331– 7. 4Espinosa ML, Nguyen MT, Aguirre AS, Martinez-Escala ME, Kim J, Walker CJ, et al. Progression of cutaneous T-cell lymphoma after dupilumab: case review of 7 patients. J Am Acad Dermatol. 2020; 83(1): 197– 9. 5Miyagaki T, Sugaya M. Immunological milieu in mycosis fungoides and Sézary syndrome. J Dermatol. 2014; 41(1): 11– 8. Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation